Systematic Financial Management LP Has $11.58 Million Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Systematic Financial Management LP grew its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 540.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 397,474 shares of the life sciences company’s stock after purchasing an additional 335,424 shares during the quarter. Systematic Financial Management LP’s holdings in Integra LifeSciences were worth $11,582,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Capital Research Global Investors increased its holdings in shares of Integra LifeSciences by 37.7% during the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after purchasing an additional 1,621,655 shares during the period. Boston Partners acquired a new stake in Integra LifeSciences in the first quarter valued at approximately $19,383,000. Cooke & Bieler LP boosted its position in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after buying an additional 388,710 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of Integra LifeSciences by 64.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after purchasing an additional 335,557 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Integra LifeSciences by 90.9% during the second quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company’s stock worth $17,436,000 after purchasing an additional 291,326 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on IART. Citigroup cut their price target on shares of Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a report on Thursday, August 22nd. JMP Securities decreased their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Truist Financial decreased their price target on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a research note on Tuesday, July 30th. Morgan Stanley lifted their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Finally, BTIG Research decreased their target price on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a research report on Wednesday, August 28th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $28.63.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $17.87 on Monday. The firm’s 50 day simple moving average is $21.33 and its 200 day simple moving average is $27.14. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $1.41 billion, a PE ratio of 35.74, a price-to-earnings-growth ratio of 0.60 and a beta of 1.10. Integra LifeSciences Holdings Co. has a 1-year low of $16.96 and a 1-year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter in the prior year, the firm earned $0.71 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.